Brought to you by 
Nobex, GSK sign $283mm oral insulin deal; cancelled
17 Nov 2003
Executive Summary
GlaxoSmithKline signed an R&D alliance covering oral insulin with drug delivery company Nobex, which could receive up to $283mm under the first project--a compound in Phase I/II trials to control blood glucose levels after meals.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nobex, GSK sign $283mm oral insulin deal; cancelled
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice